Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-valent HPV vaccine versus GARDASIL in young women
2007-003528-39Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2007
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma and 1 more comparing Nonavalent HPV VLP Vaccine with GARDASIL comparator (2 arms). Primary endpoints: Combined incidence of persistent HPV infection and HPV-related disease and Tolerability of the 9-valent HPV vaccine. Started Aug 2007; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccineqHPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal cancer
Beyond the preview
Go deeper on 2007-003528-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003528-39.